Clinical trials
Completed Pain trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
5,824 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 13 |
| 2001 | 26 |
| 2002 | 45 |
| 2003 | 58 |
| 2004 | 86 |
| 2005 | 105 |
| 2006 | 150 |
| 2007 | 163 |
| 2008 | 217 |
| 2009 | 205 |
| 2010 | 209 |
| 2011 | 248 |
| 2012 | 232 |
| 2013 | 208 |
| 2014 | 265 |
| 2015 | 234 |
| 2016 | 285 |
| 2017 | 275 |
| 2018 | 284 |
| 2019 | 320 |
| 2020 | 269 |
| 2021 | 365 |
| 2022 | 401 |
| 2023 | 391 |
| 2024 | 394 |
| 2025 | 243 |
| 2026 | 58 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5,824 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Riphah International University | 107 |
| Pfizer | 41 |
| Stanford University | 38 |
| Istanbul University - Cerrahpasa | 34 |
| Northwestern University | 33 |
| Hacettepe University | 32 |
| Mayo Clinic | 32 |
| VA Office of Research and Development | 31 |
| Ataturk University | 30 |
| TC Erciyes University | 29 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pain | 5,824 |
| Anxiety Disorders | 526 |
| Agnosia | 382 |
| Postoperative Pain | 354 |
| Chronic Pain | 224 |
| Osteoarthritis, Knee | 173 |
| Neoplasms | 172 |
| Osteoarthritis | 172 |
| Fibromyalgia | 158 |
| Fatigue | 142 |
Trials
Showing 1 to 25 of 5,824. Each trial links to its page on Pharma Observatory.
5,724 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.